Making the move to AAV producer cell lines: comparability, bridging studies and regulatory considerations

Cell and Gene Therapy Insights 2026; 12(9)

10.18609/cgti.2026.114

Published: 17 November
Podcast
Laura Sands, Ramesh Kouukuntla, Wenling Dong, Vijetha Bhat


Lauren Coyle (Editor, BioInsights) speaks with Lonza's Laura Sands (Head of Regulatory Affairs), Ramesh Koukuntla (Director of R&D), Wenling Dong (Head of Upstream Process Development), and Vijetha Bhat (Subject Expert of Platform Technologies) about:

✓
Key regulatory considerations when transitioning to AAV producer cell lines
✓
Comparability and bridging strategies to support a successful transition
✓
Approaches to managing manufacturing and regulatory risk
✓
Considerations for enabling scalable AAV production

Follow the Podcast to make sure you don't miss the next episode.

Listen to the podcast here.

If you enjoyed this episode, you can listen to all episodes from The BioInsights Podcast wherever you normally get your podcasts.

Infographic: making the move to AAV producer cell lines

If you enjoyed the podcast, view the infographic here!

View infographic



This article is part of the Vectors channel